25% of high-grade glioma patients alive 3 years post trial

Patients with recurrent high-grade glioma were treated by the University of Minnesota Medical School. Median survival was 14.4 months, compared with the typical 8 months.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news